Aprepitant

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

A potent, orally active, long-acting human NK-1 receptor (substance P receptor) antagonist with IC50 of 0.09 nM.

A potent, orally active, long-acting human NK-1 receptor (substance P receptor) antagonist with IC50 of 0.09 nM; blocks NK-1 agonist-induced foot tapping response in gerbils and shows antiemetic actions in the ferret against cisplatin challenge; has the potentiation for the treatment of peripheral pain, migraine, chemotherapy-induced emesis, and various psychiatric disorders.Chemotherapeutic Agents Approved

MK-0869;MK-869;L-754030

GPCR/G Protein

Neurokinin Receptor

NK1

Cancer

Chemotherapeutic

170729-80-3

534.43

C23H21F7N4O3

>98% (HPLC)

10 mM in DMSO

O=C1NNC(CN2[C@@H](C3=CC=C(F)C=C3)[C@@H](O[C@@H](C4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4)C)OCC2)=N1

3H-1,2,4-Triazol-3-one, 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-

(-20℃)

With Ice Pack

≥ 2 years